|A Panel Discussion of Critical New Advances in Pancreatic Cancer from ASCO-GI to the 2019 ASCO Annual Meeting|
CME, CPE, CNE
Eileen M. O’Reilly, MD - Chairperson; Tanios Bekaii-Saab, MD, FACP; and Andrea Wang-Gillam, MD, PhD
|Release Date: July 24, 2019|
Expiration Date: July 24, 2020
Pancreatic cancer treatment options has shown slow progress in the past few years, however, recent studies suggest there may be new options on the horizon. Expert faculty will review some of the most relevant data from the 2019 ASCO-GI and 2019 ASCO Annual Meeting, and explain how this data may be clinically applicable in future practice. In this activity, Dr. Bekaii-Saab and Dr. Wang-Gillam will provide highlights from some of the select poster sessions. In addition, faculty will share data analysis from two very important trials presented at ASCO 2019. The first was presented as a Plenary Session this year looking at PARP inhibitors in the maintenance setting of pancreatic cancer in patients (POLO Trial) as well as APACT: A Phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine for surgically resected pancreatic adenocarcinoma abstract data.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation, Ipsen, and Merck & Co., Inc.
|Begin, Earn CreditView Only, No Credit|